Results 101 to 110 of about 98,145 (299)
Alimentary Pharmacology &Therapeutics, EarlyView.In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi +6 more
wiley +1 more source
Journal of the Formosan Medical AssociationBackground: /Purpose: To achieve the World Health Organization goal of eliminating viral hepatitis by 2030, a key strategy in resource-limited areas is to identify the areas with high prevalence and to prioritize screening and treatment intervention.
Chien-Hung Chen +12 more
doaj +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Investigating Effects of Hepatitis C Virus on Platelet Parameters in Hemodialysis Patients
Turkish Journal of Nephrology, 2019 AIM: In this study, we aimed to investigate the effects of hepatitis C virus on platelet parameters in hemodialysis patients. MATERIALS and METHODS: We included patients who received hemodialysis in Van region in Turkey.
İdris ŞAHİN +5 more
doaj
SEROPREVALENCE OF HBsAg (HBS) AND ANTI-HCV
The Professional Medical Journal, 2018 Background: Hepatitis is the inflammation of liver caused by infectious and noninfectiousagents. Hepatitis B and C are inflammations of liver caused by the viruses which are themajor public health problems worldwide and the incidence is even more in our country.Objective: Objective of the study was, 1).
Abdul Salam +4 more
openaire +2 more sources
Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries
British Journal of Pharmacology, EarlyView.Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley +1 more source
Humoral Immune Response in Japanese Acute Hepatitis Patients with Hepatitis C Virus Infection
Canadian Journal of Gastroenterology, 2000 The humoral immune response to acute infection by hepatitis C virus (HCV) is not yet perfectly clear in terms of immunoglobulin (Ig) response, diversity of HCV antigen, and the relation with hepatitis severity and antibody response.
N Yamaguchi +3 more
doaj +1 more source
Cell Proliferation, EarlyView.AREG coordinates cell proliferation and lipid metabolism reprogramming during liver regeneration and targeting lipid metabolism can promote liver regeneration. ABSTRACT Hepatocyte proliferation restores liver mass after partial hepatectomy (PHx), but the metabolic cost of this process remains unclear.
Yuelei Hu +7 more
wiley +1 more source